NanoViricides, Inc. (NYSE American: NNVC) announced that it will present at NIBA’s 152nd Investment Conference in Fort Lauderdale on March 12, where President and Executive Chairman Anil R. Diwan will outline progress on the company’s broad-spectrum antiviral platform. The company also reported that manufacturing of its NV-387 Oral Gummies drug product has been completed in preparation for patient dosing once clinical sites are ready, as the therapy advances toward a Phase II trial for monkeypox in the Democratic Republic of Congo following a successful Phase I safety study in healthy volunteers.
The completion of NV-387 Oral Gummies manufacturing marks a significant milestone for NanoViricides, as it enables the company to move forward with patient dosing. The drug is being developed as a broad-spectrum antiviral with potential applications against RSV, COVID, Long COVID, Influenza, and other respiratory viral infections. Additionally, NV-387 has shown effectiveness in animal models for monkeypox, smallpox, and measles, making it a promising candidate for emerging infectious disease threats.
The upcoming presentation at the NIBA conference provides an opportunity for NanoViricides to share its progress with the investment community. Anil R. Diwan is expected to discuss the company’s platform technology and the implications of NV-387’s development for public health. The company emphasizes that NV-387 has successfully completed a Phase I human clinical trial in healthy volunteers with no reported adverse events, positioning it for Phase II trials.
NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is a broad-spectrum antiviral that targets multiple viral families. The company’s other advanced drug candidate, NV-HHV-1, is being developed for herpesvirus infections including HSV-1, HSV-2, VZV shingles, and chickenpox. However, the company cannot project an exact date for filing an IND for any of its drugs due to dependence on external collaborators and consultants.
The news of NV-387’s advancement is particularly relevant given the ongoing global need for effective antiviral treatments. The potential to treat a wide range of viral infections, including monkeypox, could address significant unmet medical needs. For more information on NanoViricides and its pipeline, visit the company’s newsroom at https://ibn.fm/NNVC.
